Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Haematological Malignancies Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
John C. Byrd, Peter Hillmen, Paolo Ghia, et al.
The study authors conclude from their first head-to-head trial of BTKis in CLL, that acalabrutinib showed a non-inferior progression-free survival. There were less cardiotoxicity and fewer discontinuations due to adverse events vs ibrutinib observed. Clinical trial information: NCT02477696
Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
Paolo Ghia, John N. Allan, Tanya Siddiqi, et al.
The study authors show, that with the 1st-line ibrutinib plus venetoclax all-oral, once-daily, chemotherapy-free, fixed-duration regimen deep, durable responses in patients with CLL/SLL were achieved without new safety signals.This includes those with genomic high-risk features. Clinical trial information: NCT02910583
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
Sikander Ailawadhi, Asher Alban Akmal Chanan-Khan, Zi Chen, et al.
The study authors show, that Lisaftoclax - a novel, potent, selective BCL-2i - was well tolerated with up to 1,200 mg/day. The overall response rate in R/R CLL/SLL patients was 85.7%. Grade 3-4 transient adverse events were infrequent, even at dose levels of 800 mg and above. This drug with a favorable preliminary safety profile offers a treatment alternative for patients with R/R CLL/SLL and other HMs. The daily ramp-up schedule may be more “user friendly”. Clinical trial information: NCT03537482
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.
Mitchell Reed Smith, Opeyemi Jegede, Peter Martin, et al.
The study authors show, that Bortezomib did not significantly improve the primary endpoint of progression-free survival when added to bendamustine-rituximab as initial mantle cell lymphoma therapy. ORR and CR rates at end of induction were also similar. Clinical trial information: NCT01415752
Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice.
Peter Martin, Michael Wang, Anita Kumar, et al.
The study authors conclude that In this large real-world cohort of primarily community-based US practices, median 1st-line time to next therapy for MCL pts was around 2 years. Bendamustine-rituximab was the most commonly used 1st-line therapy. Autologous stem cell transplantation was uncommon even in patients below 65 years. This suggests that real-world considerations may influence autologous stem cell transplantation eligibility and availability. Older age and high-risk disease features were predictive of worse outcomes in real-world, while rituximab maintenance appeared to be associated with better outcomes. This study shows, that outcomes across the board appear worse than prospective trials. This suggests a need to focus on developing therapies that can be delivered effectively in the community setting.
The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.
Tycel Jovelle Phillips, Alexey Valeryevich Danilov, David Alan Bond, et al.
The study authors present Interim results showing that in patients with newly diagnosed MCL at the median treatment duration the combination of venetoclax 400 mg daily, lenalidomide 20 mg, with rituximab is safe with high overall response and minimal residual disease. The toxicity profile is manageable and no new safety signals were observed. Updated results including BH3 profiling are presented at the meeting. Clinical trial information: NCT03523975
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).
Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, et al.
The study authors conclude, that MTRA induction followed by myeloablative consolidation (Arm A) had improved progression-free survival versus MTRA induction followed by non-myeloablative consolidation (Arm B). There were more progressions or deaths leading to treatment discontinuation prior to consolidation in Arm B observed. Both consolidation regimens were well-tolerated. The progression-free and overall survival rates in the newly diagnosed primary central nervous system lymphoma were encouraging. Clinical trial information: NCT01511562
Ann S. LaCasce, Travis Dockter, Amy S. Ruppert, et al.
The study authors observed excellent progression-free survival outcomes in all patients using a PET-adapted approach that allowed the omission of radiotherapy in almost four of five patients. PET2+ patients treated with escalation to BEACOPP and consolidative radiotherapy had not inferior outcomes. Clinical trial information: NCT01118026
Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
Stephen J. Schuster, Michael J. Dickinson, Martin H. Dreyling, et al.
The study authors demonstrate with their data the efficacy and acceptable safety of tisagenlecleucel in patients with r/r FL, including high-risk patients after multiple lines of prior therapy. The data suggest that tisagenlecleucel may be a promising therapy for patients with r/r FL. Clinical trial information: NCT03568461